ROSE 010

Drug Profile

ROSE 010

Alternative Names: GTP-010; LY-307161 SR; ROSE-010

Latest Information Update: 21 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Rose Pharma
  • Class Antihyperglycaemics; Glucagon-like peptides; Peptides
  • Mechanism of Action Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Dyspepsia; Irritable bowel syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 22 Oct 2008 Efficacy and adverse events data from a phase IIa trial in Irritable bowel syndrome presented at the 16th United European Gastroenterology Week (UEGW-2008)
  • 22 May 2008 Final efficacy data from a phase II trial in Irritable bowel syndrome presented at Digestive Disease Week 2008 (DDW-2008)
  • 13 Oct 2003 Discontinued - Phase-II for Type-2 diabetes mellitus in Europe (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top